Thank you again for submitting you manuscript EMBOJ-2017-98589, "TSC1 is required for tumor maintenance in MYC-driven Burkitt's lymphoma", to our journal. We have now received comments from two arbitrating referees, which I am enclosing below for your information. While the reports express some interest in the work, I am afraid that despite the previous responses and revisions available to them, neither referee considered the paper ready for EMBO Journal publication in the present form. Even though there may be some confusion in referee 1's reading of the Myc-miR-15-TSC1 axis, both referees bring up several apparently well-taken points to address prior to publication. I realize that after the significant revision efforts you already spent on this study, you may not be prepared to embark on further follow-up investigations here, and that you also may have already attempted some of the requested experiments in the past. Therefore, I would at this point like to give you the opportunity to consider the referees' comments and provide a tentative response letter detailing which further experiments you would be willing/able to undertake in order to address the referees' concerns, or how else you could envision answering their comments. Based on such a draft response, we could then work out whether or not it would be reasonable to invite and pursue a revision of this study for The EMBO Journal (or, possibly, one of our sister journals). I would therefore appreciate if you could confer with your coworkers and send us such a response at your earliest convenience, ideally over the course of next week. Should you have any further questions in this regard, of course please do not hesitate to let me know.
REFEREE COMMENTS:
Arbitrating Referee #1
The manuscript by Hartleben et al. reports the intriguing observation that MYC (Bukitt lymphoma and a MYC-inducible B cell P493 lymphoma model) represses TSC1 via miR-15a to attenuate mTOR activity. The evidence suggests fine-tuning of mTOR activity, such that excessive mTOR activity is incompatible with high MYC levels in several model systems. The authors have satisfied most previous reviewers with additional experimental evidence. This story has been presented orally publically previously, and it is commendable that the authors persisted to publish their intriguing findings that counters some prevailing concepts. It appears that the authors have cautiously nuanced their narrative regarding the interplay between MYC and mTOR. There are several items that would improve the scholarship of this manuscript. (2011)) suggests a similar interaction between MYC and TSC2 in the growth and proliferation of midgut cells in adult Drosophila. In particular, these authors show that excessive TOR-mediated growth (loss of TSC2) inhibits cell division unless dMYC levels were lowered. 3. Reviewer 4 has an important point: "In the original question #2, the reviewer pointed out that, in U2OS MycER cells, the authors showed that TSC1 knockdown led to synthetic lethality under Myc induction condition, however, in this same cell line, Myc induction did not even affect TSC1 expression.
In the rebuttal letter, the authors argue that they have provided plenty of other evidences that Myc can induce TSC1 expression (as shown in Fig 1) , and they simply use U2OS cells (in which Myc does not affect TSC1 expression) to demonstrate the synthetic lethality (Note that even the validity of this conclusion is challenged in question 1).
In this reviewer's opinion, there is a logical issue here which undermines their hypothesis that induction of TSC1 by deregulated c-Myc is required for survival of c-Myc expressing cancer cells (as stated in the last paragraph of page 6): if Myc does not induce TSC1 expression, how would they explain the dependency of Myc high cells on TSC1 for survival? Again, the reviewer argue that this actually suggest that TSC1 is important for survival in both Myc-low and Myc-high cells (not specific for Myc high cells)." I believe that these are important issues, particular with the use of the U2OS MYC-ER system. The authors did not perform any time course experiments to document how MYC in this system affects mTOR signaling through immunoblots of mTOR, p-TOR, S6, p-S6, 4EBP, and p-4EBP. Hence, these experiments should be discussed with caution, particularly, since U2OS cells do not tolerate MYC over-expression beyond 4-5 days. Whether nutrient deprivation from uncontrolled MYC and increased mTOR activity contribute to death is not addressed.
Arbitrating Referee #2
Hartleben et. al. show a requirement for TSC1 in MYC-driven lymphoma. They use cell lines, xenograft models and patient data to show that MYC-high lymphomas have high TSC1 levels, needed for maintenance of the tumors. The authors show that MYC upregulates TSC1 by increasing TSC1 mRNA stability. Moreover, knock down of TSC1 in cells with high levels of MYC causes apoptosis by increasing mitochondrial respiration and ROS generation. Specific comments on the manuscript are as follows:
1. The authors show that MYC acts primarily through miR-15 to affect TSC1 levels. They should determine the level of miRNA-15 in their panel of low MYC cell lines. In support of their claim of an MYC-miR15-TSC1 axis, miR-15 expression should inversely correlate with MYC expression. The authors should also test for cell viability upon induction of miR-15 in a high MYC background. 2. To determine whether the effect of TSC1 KD in high MYC cell lines is dependent on the TSC1-TSC2 complex-mTOR signaling axis, i.e., not an mTOR independent effect, the authors should knock down TSC2 and obtain results similar to the TSC1 KD. These experiments would further solidify their mechanism that TSC1 actions are via the TSC1-TSC2 complex. 3. Upon knockdown of TSC1 in high MYC expressing cells, the authors see upregulation of mTORC1 signaling (as expected). Such upregulation could inhibit AKT through the negative feedback loop in the mTORC1 pathway. As AKT is known to promote cell survival, its reduction in high MYC cells could cause cell death. The authors should explore this possibility by examining AKT levels in the cells in which they KD TSC1 and include the results in the manuscript. An effect through AKT could dramatically change their model. Thank you very much for considering our manuscript. I am really grateful for the time you and the reviewers spend on this. We have dealt with the reviewer's comments in detail. Please see the attached word file. For some comments we already can provide data, for others the reviewer simply overlooked data that are already in. Those issues that are left can be easily addressed experimentally, although -will all respect -we doubt that they will improve the paper or change the conclusion (we try to explain in the replies). That is why I phrase like "if the reviewer thinks it is required we do the experiment".
Arbitrating Referee #1 We will discuss this paper in a revised version of the manuscript.
We do show high expression of TSC2 together with TSC1 in high MYC expressing BL cells (cell lines: Fig. 1A , B, C, D, E, patient tumors: 2B).
To strengthen the MYC-TSC1/2 regulation beyond Burkitt's lymphoma we have data on MYC knockdown and TSC1-S6K(-P) analysis in MCF7 (breast cancer), HEK293T (embryonic kidney) and C33A (cervix carcinoma) cell lines showing that reduction of MYC results in decreased TSC1 expression and enhanced mTORC1 signaling (increase in S6K-P). We can include these data.
Amcheslavsky et al. (JCB, 193
:695 (2011)) suggests a similar interaction between MYC and TSC2 in the growth and proliferation of midgut cells in adult Drosophila. In particular, these authors show that excessive TOR-mediated growth (loss of TSC2) inhibits cell division unless dMYC levels were lowered. We will discuss this paper in a revised version of the manuscript.
Although the biological context (Drosophila) and consequence (inhibition of cell division) of TOR hyperactivation is different, also here high MYC levels are incompatible with high TOR activation, supporting that this is a more general phenomena.
3. Reviewer 4 has an important point: "In the original question #2, the reviewer pointed out that, in U2OS MycER cells, the authors showed that TSC1 knockdown led to synthetic lethality under Myc induction condition, however, in this same cell line, Myc induction did not even affect TSC1 expression.
We have blots showing expression of TSC1, S6K/S6K-P and tubulin loading control. Notably, U2OS is not a BL cell line. We do not claim that TSC1 expression is under the control of MYC in all cell types, but that also in such an occasion cell survival depends on the presence of TSC1 under high MYC expression, and that cell survival can be rescued under TSC1 KD condition either by lowering MYC or inhibition of mTORC1 by rapamycin treatment (shown in Figure 3C ).
In this reviewer's opinion, there is a logical issue here which undermines their hypothesis that induction of TSC1 by deregulated c-Myc is required for survival of c-Myc expressing cancer cells (as stated in the last paragraph of page 6): if Myc does not induce TSC1 expression, how would they explain the dependency of Myc high cells on TSC1 for survival? Again, the reviewer argue that this actually suggest that TSC1 is important for survival in both Myc-low and Myc-high cells (not specific for Myc high cells)." As a reaction on this comment we added data showing that TCS1 KD does not affect survival in MYC low HL cells (Fig. EV3E) . We do explain, why high MYC cells depend on TSC1 (even if the expression is not always under its control): it is needed to suppress mTORC1 to lower ROS production ( Fig. E-G 
)(!)
I believe that these are important issues, particular with the use of the U2OS MYC-ER system. The authors did not perform any time course experiments to document how MYC in this system affects mTOR signaling through immunoblots of mTOR, p-TOR, S6, p-S6, 4EBP, and p-4EBP.
Hence, these experiments should be discussed with caution, particularly, since U2OS cells do not tolerate MYC over-expression beyond 4-5 days. Whether nutrient deprivation from uncontrolled MYC and increased mTOR activity contribute to death is not addressed.
Maybe the best solution is to improve the description of this experiment and more cautiously phrase the conclusion? Alternatively, we could remove these data because of the known incompatibility of U2OS with high-MYC expression for longer time, which makes interpretation rather difficult The reviewer may have missed out the most important data on this presented in Table EV1 that was retrieved from a paper from our co-authors (Robertus et al We can examine cell viability after miR-15 overexpression.
We do show that miR-15a overexpression increases oxygen consumption (OCR) in Fig. 5H . The question is if miR-15a will be sufficient. As we show and discuss (and others showed) other miRs are suppressed by MYC that have seed-sequences in the TSC1-3'UTR (Table EV1 AND 
ATP (rfu)
2. To determine whether the effect of TSC1 KD in high MYC cell lines is dependent on the TSC1-TSC2 complex-mTOR signaling axis, i.e., not an mTOR independent effect, the authors should knock down TSC2 and obtain results similar to the TSC1 KD. These experiments would further solidify their mechanism that TSC1 actions are via the TSC1-TSC2 complex.
We can perform the proposed TSC2 KD experiments.
3. Upon knockdown of TSC1 in high MYC expressing cells, the authors see upregulation of mTORC1 signaling (as expected). Such upregulation could inhibit AKT through the negative feedback loop in the mTORC1 pathway. As AKT is known to promote cell survival, its reduction in high MYC cells could cause cell death. The authors should explore this possibility by examining AKT levels in the cells in which they KD TSC1 and include the results in the manuscript. An effect through AKT could dramatically change their model.
The reviewer means the mTORC1-S6K dependent IRS1-phosphorylation (negative insulin signaling feedback) resulting in decrease in AKT-Thr308-phosphorylation. However, in B cells mTORC1 is thought to be activated through B-cell receptor signaling, and it seems not to be known if IRS1 plays a role as in insulin sensitive cells. Nevertheless, we can perform AKT-Thr308-phosphorylation analysis in TSC1 KD cells.
Also in case of AKT contributing to the reduced cell survival our results show that the increased respiration and ROS production under high MYC and mTORC1 signaling can be reverted by either rapamycin treatment or MYC suppression and restores cell survival (Fig. 4E-G) . Thus, our model will not change "dramatically".
1st Editorial Decision 21st Dec 2017
Thank you very much for your response letter and proposal for revising your manuscript in response to the arbitrating referees' comments. I am happy to read that you seem to be in a position to answer the remaining points with new data/experiments and/or additional clarifications. Therefore, I would like to invite you to prepare a revised version as outlined in your response letter. Regarding the comments of arbitrator 1, please incorporate the data you already have as suggested, while for his/her last point, better description and discussion should indeed be sufficient and no data removal nor additional time course experiment required in light of your clarifications. On the other hand, I think incorporating that all proposed experiments answering to arbitrator 2's points would indeed be helpful to back up the study as it stands. With these revisions and additional textual clarifications, we should be ready to consider the paper further for eventual publication in The EMBO Journal.
Revision Response to Arbitrating Referees 29th June 2018
Dear Reviewers, dear editor, Thank you for considering our revised manuscript and for you patience. We have addressed all your concerns and you will find a point-to-point below. All changes and new figure annotations in the text are in red.
We hope you now will find the accumulated evidence strong enough to be published in EMBO Journal.
We propose to make a small change in the title: We now discuss this paper in at page 11 that shows TSC2 transcriptional downregulation by Myc.in Rat1A-based rat fibroblasts.
We do observe high expression of TSC2 together with TSC1 in high MYC expressing BL cells compared to low TSC1 and TSC2 expression in low MYC HL cells (cell lines: Fig. 1A , B, C, E, patient tumors: 2B).
To strengthen the MYC-TSC regulation beyond Burkitt's lymphoma we have data on MYC knockdown and TSC1-S6K(-P) analysis in MCF7 (breast cancer), HEK293T (embryonic kidney) and C33A (cervix carcinoma) cell lines showing that reduction of MYC results in decreased TSC1 expression and enhanced mTORC1 signaling (increase in S6K-P).
Since they are not related to Burkitt's lymphoma, we choose not to include the data in the manuscript but to show these data here. If the reviewer wishes we will of course include them in the manuscript.
Amcheslavsky et al. (JCB, 193:695 (2011)) suggests a similar interaction between MYC
and TSC2 in the growth and proliferation of midgut cells in adult Drosophila. In particular, these authors show that excessive TOR-mediated growth (loss of TSC2) inhibits cell division unless dMYC levels were lowered.
We now discuss this paper at page 11.
Although the biological context (Drosophila) and consequence (inhibition of cell division) of TOR hyperactivation is different, also here high MYC levels are incompatible with high TOR activation, supporting that this is a more general phenomena. We now also show that knockdown of TSC2 similar to TSC1 does raise mitochondrial respiration and ROS production and decreases cell survival in BL cell lines ( Figures EV3G EV4F) 3. Reviewer 4 has an important point:
"In the original question #2, the reviewer pointed out that, in U2OS MycER cells, the authors showed that TSC1 knockdown led to synthetic lethality under Myc induction condition, however, in this same cell line, Myc induction did not even affect TSC1 expression.
The U2OS cell line is not a BL cell line. We do not claim that TSC1 expression is under the control of MYC in all cell types, but that also in such an occasion cell survival depends on the presence of TSC1 under high MYC expression, and that cell survival can be rescued under TSC1 KD condition either by lowering MYC or inhibition of mTORC1 by rapamycin treatment (as shown in Fig. 3C ).
In this reviewer's opinion, there is a logical issue here which undermines their hypothesis expression, how would they explain the dependency of Myc high cells on TSC1 for survival? Again, the reviewer argue that this actually suggest that TSC1 is important for survival in both Myc-low and Myc-high cells (not specific for Myc high cells)."
We have specified in the parapgraph, page 8 "BL cancer cells"
As a reaction on this concern we added data showing that TCS1 KD does not affect survival in MYC low HL cells (Fig. EV3F) .
We do explain, why high MYC cells depend on TSC1 (even if the expression is not always under its control): it is needed to suppress mTORC1 to lower ROS production ( Fig. 4E-G We now included analysis of P-S6K/S6K showing that mTORC1 signaling is decreased upon MYC induction. TSC1 KD, even in the presence of activated MYC, leads to increased mTORC1 activity in the U2OS MYC-ER system, in Fig. EV3A In addition, a time course experiment has been published by Eilers/Murphy labs (please see figure 2d from Liu et al).
Hence, these experiments should be discussed with caution, particularly, since U2OS cells We describe a dual mechanism of TSC1 regulation. First, MYC transcriptionally controls TSC1 expression, and second, additionally represses several miRs that can downregulate TSC1 (Table EV1 and Fig. EV5A ). miR-15a has the strongest effect compared to the other miRs, but there is likely an additive effect of all miRs.
We compared the expression levels of miR-15a between high MYC BL and low MYC HL cells, but we did not observed higher miR15a levels in the tested HL cells, despite the difference in TSC1 levels (see Fig. A below) . Nevertheless, miR-15a is under control of MYC only in BL cells, and manipulation of MYC levels in HL cells has no effect on miR-15a levels (Fig. B and C below) . Therefore, the MYC-miR15a-TSC1 axis seems to be exclusively important in high MYC BL cells. BL cells probably adopted this axis as a control mechanism due to the very high MYC levels in order to keep mTORC1 in check. In cells with lower MYC levels, like the here tested HL cells, this axis is of less importance with no need to balance MYC and mTORC1 activity, so MYC does not take control over miR15-TSC1. This is also reflected in the low TSC1 levels in these cells.
Because the miR expression data in HL versus BL cell lines are inconclusive we did not included them in the manuscript.
In addition, we now show that miR-15a overexpression results in reduced BL cell viability ( Please also see the data on this presented in Table EV1 that 2. To determine whether the effect of TSC1 KD in high MYC cell lines is dependent on the TSC1-TSC2 complex-mTOR signaling axis, i.e., not an mTOR independent effect, the authors should knock down TSC2 and obtain results similar to the TSC1 KD. These experiments would further solidify their mechanism that TSC1 actions are via the TSC1-TSC2 complex.
We added the following data for TSC2 knockdown. In addition, our experiment showing that TSC1 KD induced cell death can be rescued by rapamycin (Fig. 3B) indicates that cell death is mediated through mTORC1.
Together, the results support our model where the TSC1/2 complex is required to control mTORC1 and secure survival in high MYC BL cells. We tried hard to show Thr-308 phosphorylation as well but failed to do so both in TSC1
knockdown and control cells (although we can detect pan AKT).
Together with our rapamycin and antioxidant rescue experiments ( Fig. 3B, E; 4A, C-G) altogether our data suggest that mTORC1 hyperactivation and not decreased AKT activity is responsible for the increased cell death. Possibly the increase in Ser-493 AKT phosphorylation is a secondary compensatory effect to counteract the cell death by mTORC1 hyperactivation. Thank you for submitting your final revised manuscript. I am sorry for the delay in dealing with it, but I have now finally had a chance to carefully look through your responses and new data, and I am happy to let you know that I see no further objections towards publication. We have therefore now accepted it for publication in The EMBO Journal! 1.a. How was the sample size chosen to ensure adequate power to detect a pre--specified effect size?
1.b. For animal studies, include a statement about sample size estimate even if no statistical methods were used.
2. Describe inclusion/exclusion criteria if samples or animals were excluded from the analysis. Were the criteria pre--established?
3. Were any steps taken to minimize the effects of subjective bias when allocating animals/samples to treatment (e.g. randomization procedure)? If yes, please describe.
For animal studies, include a statement about randomization even if no randomization was used.
4.a. Were any steps taken to minimize the effects of subjective bias during group allocation or/and when assessing results (e.g. blinding of the investigator)? If yes please describe. Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
definitions of statistical methods and measures:
a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
Please fill out these boxes # (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
C--Reagents

B--Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified the exact sample size (n) for each experimental group/condition, given as a number, not a range;
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.
YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND #
It was chosen baseon on earlier experiments performed in the lab using the same technique
The animal experiment (xenograft) was performed through a company and the sample size estimate was based on their professional experience
No animals or samples were excluded.
if applicable, samples were not allocated by name but by numbering
The single animal experiment (xenograft) was performed by a company and was not randomized
Part of the experiments were performed by technical staff members who only worked with samples allocated by numbers. For other experiments the investigator was not blinded.
The single animal experiment (xenograft) included in the manuscript was performed by a company and the investigators were not blinded during the experiment yes, reportet in the figure legends yes, we used visual inspection for assessment yes, with the exception of the westernblots from visual inspection the variance seems to be similar
